A 52-year-old woman presents with vulvovaginal atrophy symptoms including severe dyspareunia and vaginal dryness. She experienced natural menopause 3 years ago. She has a history of oestrogen receptor-positive breast cancer treated with wide local excision and radiotherapy 18 months ago. She is currently taking tamoxifen and will continue this for at least 3 more years. Her oncologist has cleared her to seek gynaecological advice for her symptoms. What is the most appropriate initial management?
Q62
A 30-year-old woman with a history of superficial venous thrombosis in her left leg during pregnancy 2 years ago presents requesting contraception. She completed 6 weeks of anticoagulation at the time. She is not currently breastfeeding, has a BMI of 25 kg/m², and does not smoke. Thrombophilia screening performed after the event showed no abnormalities. Which contraceptive method would be most appropriate according to UKMEC?
Q63
A 56-year-old woman who underwent total hysterectomy with bilateral salpingo-oophorectomy at age 42 for endometriosis has been taking continuous oestrogen-only HRT (transdermal estradiol 50 mcg twice weekly) since her surgery. She is now concerned about long-term HRT use after reading about risks online. She continues to experience joint pains and low mood when she has tried to stop HRT previously. What is the most appropriate advice regarding continuation of her HRT?
Q64
A 47-year-old woman presents with a 4-month history of irregular menstrual cycles, hot flushes, and mood changes. She uses condoms for contraception and wishes to continue with effective contraception. Her FSH level measured on day 2 of her cycle is 42 IU/L. She asks how long she needs to continue contraception. What is the most appropriate advice?
Q65
A 34-year-old nulliparous woman with von Willebrand disease type 1 presents requesting contraception. She experiences regular menstrual cycles but has menorrhagia requiring tranexamic acid. She is in a stable relationship and wishes to avoid pregnancy for at least 5 years. Her BMI is 26 kg/m², blood pressure is 120/78 mmHg, and she does not smoke. Which contraceptive method would be most appropriate for this patient?
Q66
A 51-year-old woman presents with severe hot flushes and night sweats affecting her quality of life. Her last menstrual period was 8 months ago. She is keen to start hormone replacement therapy but is concerned about cardiovascular risks. She has a BMI of 27 kg/m², does not smoke, and her blood pressure is 134/84 mmHg. She has no personal or family history of cardiovascular disease or breast cancer. She had a normal cervical screening test 18 months ago and normal mammography 6 months ago. What is the most appropriate initial advice regarding HRT and cardiovascular risk in this patient?
Q67
A 23-year-old woman attends for contraceptive counselling. She requests the combined oral contraceptive pill. Her mother was diagnosed with venous thromboembolism at age 55 during prolonged immobilisation following a fractured femur. The patient has no personal history of thrombosis, does not smoke, and has a BMI of 24 kg/m². Her blood pressure is 118/76 mmHg. According to the UK Medical Eligibility Criteria for Contraceptive Use (UKMEC), what is the classification for combined hormonal contraception in this patient?
Q68
A 55-year-old woman presents for review of her HRT. She commenced transdermal oestradiol patches and oral micronised progesterone 2 years ago for menopausal symptoms. Her vasomotor symptoms are now well controlled. She underwent total abdominal hysterectomy for fibroids at age 44. She asks whether she needs to continue taking the progesterone. What is the most appropriate advice?
Q69
What is the recommended duration for continuation of contraception after permanent cessation of menses in a woman who experiences menopause at age 48?
Q70
A 49-year-old woman presents with increasingly frequent hot flushes. She has a history of oestrogen receptor-positive breast cancer treated with wide local excision and radiotherapy 4 years ago. She is currently taking tamoxifen. Her vasomotor symptoms are significantly affecting her quality of life and sleep. What is the most appropriate management for her menopausal symptoms?
Reproductive Health UK Medical PG Practice Questions and MCQs
Question 61: A 52-year-old woman presents with vulvovaginal atrophy symptoms including severe dyspareunia and vaginal dryness. She experienced natural menopause 3 years ago. She has a history of oestrogen receptor-positive breast cancer treated with wide local excision and radiotherapy 18 months ago. She is currently taking tamoxifen and will continue this for at least 3 more years. Her oncologist has cleared her to seek gynaecological advice for her symptoms. What is the most appropriate initial management?
A. Vaginal oestrogen therapy is contraindicated and non-hormonal lubricants should be recommended
B. Systemic HRT at the lowest dose for shortest duration
C. Vaginal oestrogen therapy can be offered after discussion with oncologist, as systemic absorption is minimal (Correct Answer)
D. Intravaginal testosterone therapy
E. Vaginal dehydroepiandrosterone (DHEA)
Explanation: ***Vaginal oestrogen therapy can be offered after discussion with oncologist, as systemic absorption is minimal***
- For women with a history of **oestrogen receptor-positive breast cancer**, local vaginal oestrogen is considered an option when non-hormonal treatments fail, as **systemic absorption** remains within the normal postmenopausal range.
- **Guidelines (BMS/NICE)** advocate for a shared decision-making process involving the patient and her **oncologist** to balance quality of life against potential recurrence risks.
*Vaginal oestrogen therapy is contraindicated and non-hormonal lubricants should be recommended*
- While **non-hormonal lubricants** are usually first-line, vaginal oestrogens are not strictly contraindicated in breast cancer survivors if symptoms are resistant and severe.
- This approach is too restrictive for a patient with **severe dyspareunia** who has already received oncological clearance for specialist gynaecological advice.
*Systemic HRT at the lowest dose for shortest duration*
- **Systemic HRT** is generally avoided in patients with a history of **ER-positive breast cancer** due to the significantly higher risk of stimulating micrometastases.
- Local therapy is preferred over systemic therapy for managing isolated **genitourinary syndrome of menopause** (GSM) in cancer survivors.
*Intravaginal testosterone therapy*
- **Intravaginal testosterone** is not a standard licensed treatment for **vulvovaginal atrophy** in the UK and lacks robust long-term safety data in breast cancer patients.
- It is generally reserved for **libido issues** (HSDD) in a systemic form rather than as a primary treatment for vaginal dryness.
*Vaginal dehydroepiandrosterone (DHEA)*
- Although **Prasterone (DHEA)** is an effective treatment for vulvovaginal atrophy, **vaginal oestrogen** is usually preferred initially as it has much more established evidence and wider availability.
- Like oestrogen, its use in breast cancer requires **oncological consultation**, making vaginal oestrogen the more conventional starting point for hormonal management.
Question 62: A 30-year-old woman with a history of superficial venous thrombosis in her left leg during pregnancy 2 years ago presents requesting contraception. She completed 6 weeks of anticoagulation at the time. She is not currently breastfeeding, has a BMI of 25 kg/m², and does not smoke. Thrombophilia screening performed after the event showed no abnormalities. Which contraceptive method would be most appropriate according to UKMEC?
A. Combined oral contraceptive pill
B. Progestogen-only implant (Correct Answer)
C. Depot medroxyprogesterone acetate injection
D. Combined contraceptive vaginal ring
E. No hormonal contraception can be used due to history of thrombosis
Explanation: ***Progestogen-only implant***- For women with a history of **venous thromboembolism** or superficial venous thrombosis, progestogen-only methods are classified as **UKMEC 1**, meaning there are no restrictions on use.- These methods do not increase the risk of **VTE**, making them safe and highly effective **Long-Acting Reversible Contraception (LARC)** options in patients with a history of thrombosis.*Combined oral contraceptive pill*- The **Combined oral contraceptive pill** contains estrogen, which increases the liver's production of clotting factors and is generally avoided or used with caution (**UKMEC 2/3**) in patients with a history of thrombosis.- Although a single episode of **superficial venous thrombosis** in pregnancy is a lower risk, estrogen-containing methods are less ideal than progestogen-only alternatives in this context.*Depot medroxyprogesterone acetate injection*- While this is also a **UKMEC 1** option for history of VTE, it is often considered secondary to the implant or IUS because it is not as easily **reversible** and may impact **bone mineral density** over long-term use.- It is a safe alternative, but the **progestogen-only implant** is generally preferred as a first-line LARC due to its higher efficacy and superior side-effect profile.*Combined contraceptive vaginal ring*- This is a **combined hormonal contraceptive** that delivers estrogen systemically, carrying the same increased risk of **thromboembolism** as the combined pill.- It is classified similarly to other combined methods and is less appropriate than **progestogen-only** methods in patients with a history of vascular events.*No hormonal contraception can be used due to history of thrombosis*- This is incorrect because **progestogen-only contraceptives** (pills, implants, injections) do not carry the same clotting risks as estrogen-based methods.- Only **combined hormonal contraception** is restricted; patients with a history of thrombosis can safely use all forms of progestogen-only or **non-hormonal** (copper IUD) methods.
Question 63: A 56-year-old woman who underwent total hysterectomy with bilateral salpingo-oophorectomy at age 42 for endometriosis has been taking continuous oestrogen-only HRT (transdermal estradiol 50 mcg twice weekly) since her surgery. She is now concerned about long-term HRT use after reading about risks online. She continues to experience joint pains and low mood when she has tried to stop HRT previously. What is the most appropriate advice regarding continuation of her HRT?
A. HRT must be stopped immediately as she has exceeded the maximum recommended duration of 5 years
B. Continue HRT until age 60, then gradually reduce and stop
C. HRT can be continued for symptom control as she had premature ovarian insufficiency, with benefits likely outweighing risks until at least the average age of natural menopause (Correct Answer)
D. Switch to the lowest dose of HRT and plan to stop within 6 months
E. Continue current dose but add cyclical progestogen to reduce endometrial cancer risk
Explanation: ***HRT can be continued for symptom control as she had premature ovarian insufficiency, with benefits likely outweighing risks until at least the average age of natural menopause***
- This patient underwent **surgical menopause at age 42**, classifying as **early menopause** (age 40–45); guidelines recommend HRT until at least the average age of natural menopause (51 years) to mitigate cardiovascular and bone risks.
- There is no **arbitrary time limit** for HRT; as her symptoms (joint pain, low mood) recur upon stopping, continuation is appropriate based on an **individualized benefit-risk assessment**.
*HRT must be stopped immediately as she has exceeded the maximum recommended duration of 5 years*
- The "5-year rule" is an outdated concept; duration should be based on **individual clinical need** and severity of symptoms rather than a fixed cutoff.
- **Abrupt cessation** is not advised here as the patient has demonstrated significant **vasomotor or psychological symptoms** when previously attempting to stop.
*Continue HRT until age 60, then gradually reduce and stop*
- Setting a specific age like 60 is **too rigid**; decisions regarding HRT should be reviewed annually based on the patient's **evolving health profile** and symptom management.
- While gradual reduction help identify the return of symptoms, the goal should be **lowest effective dose** rather than a pre-determined stopping date.
*Switch to the lowest dose of HRT and plan to stop within 6 months*
- While using the **lowest effective dose** is a core principle, forcing a stop within 6 months is inappropriate for a patient whose **quality of life** is significantly impacted by recurrence.
- Rapid withdrawal can lead to a **rebound of menopausal symptoms**, particularly joint pain and mood instability noted in her history.
*Continue current dose but add cyclical progestogen to reduce endometrial cancer risk*
- **Progestogen** is only required for women with an **intact uterus** to prevent endometrial hyperplasia; this patient had a **total hysterectomy**.
- Adding progestogen unnecessarily would increase the risk of **breast cancer** and side effects without providing any clinical benefit in this case.
Question 64: A 47-year-old woman presents with a 4-month history of irregular menstrual cycles, hot flushes, and mood changes. She uses condoms for contraception and wishes to continue with effective contraception. Her FSH level measured on day 2 of her cycle is 42 IU/L. She asks how long she needs to continue contraception. What is the most appropriate advice?
A. Contraception can be stopped immediately as the elevated FSH confirms menopause
B. Continue contraception for 1 year after the last menstrual period (Correct Answer)
C. Continue contraception for 2 years after the last menstrual period
D. Repeat FSH in 6 weeks and stop contraception if it remains elevated
E. Continue contraception until age 55 regardless of symptoms or FSH levels
Explanation: ***Continue contraception for 1 year after the last menstrual period***- For women **over the age of 50**, it is recommended to continue contraception for **12 months** (1 year) after their last menstrual period (LMP) to ensure no unplanned pregnancies.- The patient is 47 and likely to be over 50 by the time she reaches **menopause** (defined as 12 consecutive months of amenorrhea), making this the appropriate duration.*Contraception can be stopped immediately as the elevated FSH confirms menopause*- A single **FSH level** is not sufficient to confirm menopause, especially in perimenopausal women, as levels can fluctuate significantly.- Fertility, while decreased, is not entirely absent during **perimenopause**, and contraception is still necessary.*Continue contraception for 2 years after the last menstrual period*- This recommendation applies to women who experience menopause **under the age of 50**, as they are considered to have a longer potential window of fertility.- Given the patient's age of 47 and current symptoms, she will most likely be over 50 when she reaches menopause, making the 1-year rule more applicable.*Repeat FSH in 6 weeks and stop contraception if it remains elevated*- **FSH levels** alone do not reliably indicate the permanent cessation of fertility, and repeated measurements are not recommended for guiding contraceptive cessation in women over 45 with typical symptoms.- Relying solely on FSH could lead to an early cessation of contraception and an increased risk of **unintended pregnancy**.*Continue contraception until age 55 regardless of symptoms or FSH levels*- While contraception is generally recommended until at least age 50-52 for most women, continuing until age **55** is often a safe upper limit to ensure fertility has ceased for all women, irrespective of symptoms.- However, specific guidelines based on the **last menstrual period** (LMP) are more precise for determining the actual cessation point.
Question 65: A 34-year-old nulliparous woman with von Willebrand disease type 1 presents requesting contraception. She experiences regular menstrual cycles but has menorrhagia requiring tranexamic acid. She is in a stable relationship and wishes to avoid pregnancy for at least 5 years. Her BMI is 26 kg/m², blood pressure is 120/78 mmHg, and she does not smoke. Which contraceptive method would be most appropriate for this patient?
A. Combined oral contraceptive pill
B. Copper intrauterine device
C. Levonorgestrel intrauterine system (Correct Answer)
D. Progestogen-only pill
E. Barrier methods only due to bleeding disorder contraindication
Explanation: ***Levonorgestrel intrauterine system***
- This is the ideal choice as it provides **long-acting reversible contraception (LARC)** for up to 5 years and significantly reduces **menstrual blood loss** by causing endometrial atrophy.
- It is classified as **UKMEC 1** for patients with bleeding disorders like **von Willebrand disease**, effectively managing her **menorrhagia** better than other methods.
*Combined oral contraceptive pill*
- While it can manage **menstrual flow**, it requires **daily compliance** and may be less effective in preventing pregnancy compared to the **LNG-IUS** over a 5-year period.
- The **LNG-IUS** is preferred here because it provides superior **heavy menstrual bleeding (HMB)** control while meeting the patient's request for long-term contraception.
*Copper intrauterine device*
- The **copper IUD** is contraindicated in this patient as it typically **increases menstrual blood loss** and could worsen her existing **menorrhagia**.
- It has no therapeutic benefit for a patient already requiring **tranexamic acid** for bleeding control.
*Progestogen-only pill*
- This method requires **strict daily timing** to maintain efficacy and often causes **irregular spotting** rather than the predictable reduction in bleeding desired.
- It does not offer the same high level of **menstrual suppression** or the "fit and forget" convenience of a **5-year LARC**.
*Barrier methods only due to bleeding disorder contraindication*
- Bleeding disorders are not a **contraindication** to hormonal contraception; in fact, hormonal methods are often **therapeutic** for managing bleeding symptoms.
- **Barrier methods** have a higher **failure rate** and do not address the patient's clinical need to manage her **von Willebrand-related menorrhagia**.
Question 66: A 51-year-old woman presents with severe hot flushes and night sweats affecting her quality of life. Her last menstrual period was 8 months ago. She is keen to start hormone replacement therapy but is concerned about cardiovascular risks. She has a BMI of 27 kg/m², does not smoke, and her blood pressure is 134/84 mmHg. She has no personal or family history of cardiovascular disease or breast cancer. She had a normal cervical screening test 18 months ago and normal mammography 6 months ago. What is the most appropriate initial advice regarding HRT and cardiovascular risk in this patient?
A. HRT is contraindicated due to her age being over 50 years
B. She should commence low-dose aspirin before starting HRT to reduce cardiovascular risk
C. Starting HRT within 10 years of menopause in women under 60 years is not associated with increased cardiovascular risk (Correct Answer)
D. Oral HRT carries lower cardiovascular risk than transdermal preparations in this patient
E. She requires cardiology assessment before HRT can be prescribed
Explanation: ***Starting HRT within 10 years of menopause in women under 60 years is not associated with increased cardiovascular risk***
- This patient, at 51 years old and 8 months post-menopause, falls within the **'window of opportunity'**, where initiating HRT is generally considered safe regarding **cardiovascular risk**.
- For healthy women under 60 years or within 10 years of menopause, HRT is not associated with an increased risk of **coronary heart disease** and may even offer **cardioprotective benefits**.
*HRT is contraindicated due to her age being over 50 years*
- Age over 50 is not a **contraindication** for HRT; in fact, most women start HRT in their 50s to manage **menopausal symptoms**.
- The critical factor for cardiovascular risk is the **timing of initiation** relative to menopause, rather than chronological age alone, with a preference for starting close to menopause onset.
*She should commence low-dose aspirin before starting HRT to reduce cardiovascular risk*
- There is no clinical guideline recommending **routine low-dose aspirin** prophylaxis prior to HRT initiation in healthy women without established cardiovascular disease or high-risk factors.
- Aspirin is prescribed for primary or secondary prevention of **cardiovascular events** based on individual risk assessment, not as a blanket recommendation for HRT users.
*Oral HRT carries lower cardiovascular risk than transdermal preparations in this patient*
- **Transdermal HRT** (patches, gels) generally carries a lower risk of **venous thromboembolism (VTE)** and stroke compared to oral HRT because it avoids **first-pass hepatic metabolism** through the liver.
- This makes transdermal routes often preferable, especially for women with a higher BMI (though hers is only slightly elevated) or other risk factors for VTE.
*She requires cardiology assessment before HRT can be prescribed*
- A **cardiology assessment** is unnecessary for this patient, as she presents with no symptoms or significant risk factors for **cardiovascular disease** (e.g., no personal or family history, non-smoker, normal BP).
- Standard primary care evaluation, including a detailed medical history and physical examination, is sufficient before prescribing HRT for this healthy woman.
Question 67: A 23-year-old woman attends for contraceptive counselling. She requests the combined oral contraceptive pill. Her mother was diagnosed with venous thromboembolism at age 55 during prolonged immobilisation following a fractured femur. The patient has no personal history of thrombosis, does not smoke, and has a BMI of 24 kg/m². Her blood pressure is 118/76 mmHg. According to the UK Medical Eligibility Criteria for Contraceptive Use (UKMEC), what is the classification for combined hormonal contraception in this patient?
A. UKMEC 1 - no restriction on use
B. UKMEC 2 - advantages generally outweigh risks (Correct Answer)
C. UKMEC 3 - risks generally outweigh advantages
D. UKMEC 4 - unacceptable health risk
E. Thrombophilia screening required before classification
Explanation: ***UKMEC 2 - advantages generally outweigh risks***- According to **UKMEC guidelines**, a family history of **venous thromboembolism (VTE)** in a first-degree relative aged **45 or older** is classified as **UKMEC 2**.- This patient's mother had a clear **provoking factor** (immobilization and fracture) and was older than 45, meaning the patient can safely use the pill as medical benefits outweigh the risks.*UKMEC 1 - no restriction on use*- **UKMEC 1** is reserved for patients with no risk factors at all; a family history of VTE, even if late-onset, increases risk enough to move to category 2.- Since there is a **first-degree relative** with a thrombotic event, it cannot be classified as a completely unrestricted state.*UKMEC 3 - risks generally outweigh advantages*- **UKMEC 3** would apply if the first-degree relative had suffered a VTE at an age **younger than 45**.- Because the mother's event occurred at **age 55**, the risk profile is lower, avoiding this more restrictive classification.*UKMEC 4 - unacceptable health risk*- **UKMEC 4** is assigned to patients with a **personal history of VTE** or known **thrombogenic mutations** (e.g., Factor V Leiden).- This patient has no personal history and has normal **blood pressure/BMI**, so combined hormonal contraception is not contraindicated.*Thrombophilia screening required before classification*- Routine **thrombophilia screening** is not recommended by UKMEC before starting contraception, even with a family history of VTE.- Testing is only considered if the family history suggests an **inherited disorder** (multiple early-onset events), which is not the case here.
Question 68: A 55-year-old woman presents for review of her HRT. She commenced transdermal oestradiol patches and oral micronised progesterone 2 years ago for menopausal symptoms. Her vasomotor symptoms are now well controlled. She underwent total abdominal hysterectomy for fibroids at age 44. She asks whether she needs to continue taking the progesterone. What is the most appropriate advice?
A. Continue the progesterone as she has been taking it for 2 years and stopping may cause symptom recurrence
B. Reduce the progesterone dose gradually over 3 months before stopping
C. Stop the progesterone immediately as it is not required after hysterectomy (Correct Answer)
D. Continue progesterone for another year then review
E. Continue progesterone to reduce cardiovascular risk
Explanation: ***Stop the progesterone immediately as it is not required after hysterectomy***
- In Hormone Replacement Therapy (HRT), **progesterone** is used solely to provide **endometrial protection** by preventing hyperplasia caused by unopposed estrogen.
- Since this patient has undergone a **total abdominal hysterectomy**, she has no uterus and therefore no risk of endometrial cancer, making progesterone unnecessary.
*Continue the progesterone as she has been taking it for 2 years and stopping may cause symptom recurrence*
- **Vasomotor symptoms** (hot flashes, night sweats) are managed by **estrogen**, not progesterone, so stopping progesterone will not cause these symptoms to return.
- Long-term unnecessary use of progesterone increases the risk of **breast cancer** compared to estrogen-only regimens.
*Reduce the progesterone dose gradually over 3 months before stopping*
- There is no clinical requirement for a **tapered withdrawal** of progesterone as it does not cause physiological withdrawal symptoms in this context.
- Immediate cessation is preferred to reduce the risk of side effects like **breast tenderness**, bloating, and mood changes.
*Continue progesterone for another year then review*
- There is no medical indication to continue a drug that provides **zero benefit** while increasing potential risks.
- Standard guidelines dictate that **estrogen-only HRT** is the gold standard for women without a uterus.
*Continue progesterone to reduce cardiovascular risk*
- Progesterone does not provide **cardiovascular protection** and can sometimes have a negative impact on **lipid profiles**.
- Routine use of combined HRT is generally associated with a slightly higher risk profile than **estrogen-only therapy** in postmenopausal women.
Question 69: What is the recommended duration for continuation of contraception after permanent cessation of menses in a woman who experiences menopause at age 48?
A. 1 year after the last menstrual period
B. 2 years after the last menstrual period (Correct Answer)
C. Until age 50
D. Until age 55
E. 6 months after the last menstrual period
Explanation: ***2 years after the last menstrual period***- For women who experience **menopause before age 50**, the recommended duration for continuing contraception is **two years** after the last menstrual period to ensure complete cessation of ovulation.- This precautionary period is longer for younger women because **perimenopause** tends to be more unpredictable and spontaneous ovulation is more likely than in women over 50.*1 year after the last menstrual period*- This duration is recommended for women who reach **menopause at or after age 50**, as their fertility declines more rapidly.- Using this cutoff for a 48-year-old would carry a higher risk of **unplanned pregnancy**.*Until age 50*- Contraceptive advice is based on the **time elapsed since the last menstrual period (amenorrhea)**, not strictly on reaching a specific chronological age.- Reaching age 50 does not guarantee that she has been amenorrheic for the required **two-year safety margin**.*Until age 55*- While the risk of natural conception is considered negligible after **age 55**, this is a general biological marker rather than the specific recommendation for clinical menopause management.- Recommendations focusing on the **last menstrual period** provide more tailored guidance for women experiencing earlier menopause.*6 months after the last menstrual period*- This duration is insufficient to confirm the permanent cessation of **ovarian activity** regardless of the patient's age.- Following this advice would lead to a significant risk of **ovulation and conception** during the late perimenopausal transition.
Question 70: A 49-year-old woman presents with increasingly frequent hot flushes. She has a history of oestrogen receptor-positive breast cancer treated with wide local excision and radiotherapy 4 years ago. She is currently taking tamoxifen. Her vasomotor symptoms are significantly affecting her quality of life and sleep. What is the most appropriate management for her menopausal symptoms?
A. Stop tamoxifen and commence oestrogen-only HRT
B. Prescribe venlafaxine (Correct Answer)
C. Prescribe black cohosh and evening primrose oil
D. Commence continuous combined HRT at the lowest dose
E. Prescribe clonidine
Explanation: ***Prescribe venlafaxine***
- **Venlafaxine** is a Serotonin-Norepinephrine Reuptake Inhibitor (**SNRI**) that is highly effective for treating **vasomotor symptoms** in patients where hormone therapy is contraindicated.
- It is preferred over certain SSRIs like paroxetine because it does not inhibit **CYP2D6**, meaning it will not interfere with the metabolic activation of **tamoxifen**.
*Stop tamoxifen and commence oestrogen-only HRT*
- **Tamoxifen** is essential for reducing the risk of recurrence in **oestrogen receptor-positive** breast cancer and should not be discontinued prematurely.
- Any form of **Hormone Replacement Therapy (HRT)** is strictly contraindicated in patients with a history of oestrogen-sensitive breast cancer due to the risk of **disease recurrence**.
*Prescribe black cohosh and evening primrose oil*
- These **herbal preparations** lack robust clinical evidence for efficacy and their long-term safety in **breast cancer survivors** is not well-established.
- NICE guidelines suggest that many herbal products carry a risk of **unpredictable interactions** with breast cancer treatments like tamoxifen.
*Commence continuous combined HRT at the lowest dose*
- Systemic **oestrogen** is strongly avoided in patients with a history of breast cancer, regardless of the dose or the addition of a **progestogen**.
- Combined HRT would significantly increase the **risk of recurrence** and is not an appropriate clinical choice for this patient.
*Prescribe clonidine*
- **Clonidine** has limited efficacy for hot flushes compared to SNRIs and is associated with significant side effects such as **dry mouth**, drowsiness, and **constipation**.
- It is generally considered a second-line non-hormonal option behind **venlafaxine** or gabapentinoids.
